- Institution: Stanford Univ Med Ctr Lane Med Lib/Periodical Dept/Rm L109
- Sign In as Member / Individual
Coming of Age:Anti–Cytokine Therapies
Table 1.
Development of anti-cytokine therapeutics
| Drug | Targeted cytokine | Biologic type | Indication | Clinical status | Company |
|---|---|---|---|---|---|
| Cancer | |||||
| BE-8 | IL-6 | Murine mAb | B-lympho proliferative disorder; Multiple myeloma | Phase I | Diaclone |
| AvastinTM (bevacizumab) | Vascular endothelial growth factor | Humanized mAb | Advanced breast and colorectal cancer | Phase III | Genentech |
| Autoimmune Disorder | |||||
| REMICADE® (infliximab) | TNF-α | Chimeric mAb | RA, CD; Psoriasis | Approved;Phase II/III | Johnson & Johnson/Centocor |
| Enbrel® (etanercept) | TNF-α, LT-α | Receptor/Ig fusion protein | RA, JRA, Psoriatic arthritis;Psoriasis | Approved; | Immunex |
| D2E7 (adalimumab) | TNF-α | Human mAb | RA | Phase III | Abbott |
| HuMax-IL15 | IL-15 | Human mAb | RA | Phase I/II | Genmab A/S, Immunex |
| ABX-IL-8 | IL-8 | Human mAb | Psoriasis | Phase II | Abgenix |
| KineretTM (anakinra) | IL-1 receptor | Receptor antagonist | RA | Approved | Amgen |
| Transplantation | |||||
| Simulect® (basiliximab) | IL-2Rα | Chimeric mAb | Acute kidney transplant rejection | Approved | Novartis |
| Zenapax® (daclizimab) | IL-2Rα | Humanized mAb | Acute kidney transplant rejection | Approved | Protein Design Labs/Hoffman LaRoche |
| Respiratory | |||||
| NuvanceTM (altrakincept) | IL-4 | Receptor/Ig fusion protein | Asthma | Phase II | Immunex |
| SB240683 | IL-4 | Humanized mAb | Asthma | Phase II | Protein Design Labs/GSK |
| SB240563 (mepolizumab) | IL-5 | Humanized mAb | Asthma | Phase II | GSK |
| ABX-IL-8 | IL-8 | Human mAb | Chronic obstructive pulmonary disease | Phase II | Abgenix |
